1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 46 pages

Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Rib-X Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Rib-X Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Rib-X Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Rib-X Pharmaceuticals, Inc. - Brief Rib-X Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Rib-X Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Rib-X Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Rib-X Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Rib-X Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Rib-X Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Rib-X Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Rib-X Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Rib-X Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Rib-X Pharmaceuticals, Inc. Snapshot 5
Rib-X Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Rib-X Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Rib-X Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Rib-X Pharmaceuticals, Inc. - Pipeline Products Glance 11
Rib-X Pharmaceuticals, Inc. - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Rib-X Pharmaceuticals, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Rib-X Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Rib-X Pharmaceuticals, Inc. - Drug Profiles 15
delafloxacin 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
radezolid 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
RX-02 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
RX-04 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
RX-05 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
RX-06 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
RX-P763 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
RX-P766 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
RX-P770 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
RX-P792 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
RX-P793 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
RX-P808 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Rib-X Pharmaceuticals, Inc. - Pipeline Analysis 34
Rib-X Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 34
Rib-X Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 36
Rib-X Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 37
Rib-X Pharmaceuticals, Inc. - Recent Pipeline Updates 38
Rib-X Pharmaceuticals, Inc. - Dormant Projects 43
Rib-X Pharmaceuticals, Inc. - Locations And Subsidiaries 44
Head Office 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables


Rib-X Pharmaceuticals, Inc., Key Information 5
Rib-X Pharmaceuticals, Inc., Key Facts 5
Rib-X Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Rib-X Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
Rib-X Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
Rib-X Pharmaceuticals, Inc. - Phase III, 2013 11
Rib-X Pharmaceuticals, Inc. - Phase II, 2013 12
Rib-X Pharmaceuticals, Inc. - Pre-Clinical, 2013 13
Rib-X Pharmaceuticals, Inc. - Discovery, 2013 14
Rib-X Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 35
Rib-X Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 36
Rib-X Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 37
Rib-X Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 38
Rib-X Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 43

List of Figures


Rib-X Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Rib-X Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
Rib-X Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
Rib-X Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 34
Rib-X Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 36
Rib-X Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.